Keywords: pozen/gsk, trexima, target, nda, firm, pozen, says

POZEN/GSK's Trexima on target for NDA

Article | 27 April 2005

Print This

US firm POZEN says that all primary endpoints of its second Phase III clinical trial of migraine drug Trexima (sumatriptan ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in